Metabolism of Haloperidol (Haldol)
Haloperidol undergoes extensive hepatic metabolism primarily via cytochrome P450 3A4 (CYP3A4), with additional contributions from CYP2D6, carbonyl reductase, and glucuronidation pathways.
Primary Metabolic Pathways
Haloperidol's biotransformation involves three major enzymatic systems 1:
- Glucuronidation (greatest proportion of intrinsic hepatic clearance)
- Carbonyl reduction to reduced haloperidol (RH)
- CYP-mediated oxidation (primarily CYP3A4)
CYP3A4-Mediated Metabolism
CYP3A4 is the predominant cytochrome P450 isoform responsible for haloperidol metabolism 2, 3. This enzyme catalyzes multiple pathways:
- Formation of the tetrahydropyridine analog (HTP) through dehydration
- Conversion of HTP to the pyridinium metabolite (HP+)
- N-dealkylation to 4-(4-chlorophenyl)-4-hydroxypiperidine (CPHP)
- Back-oxidation of reduced haloperidol to the parent compound 4
CYP3A5 and CYP3A7 also demonstrate catalytic activity for pyridinium formation, though CYP3A4 remains the major catalyst 2.
Additional Metabolic Enzymes
CYP2D6 participates in:
- Conversion of HTP to HP+ 4
- N-dealkylation reactions 3
- Oxidation of the reduced pyridinium analog (RHP+) to HP+ 3
CYP1A1 shows remarkably high activity (50 times greater than CYP1A2, 220 times greater than CYP3A4) for oxidizing RHP+ to HP+ 3, though its clinical relevance remains uncertain given its limited hepatic expression.
Other minor contributors include CYP2C19, CYP2C8, and CYP2C9 for N-dealkylation 3.
Key Metabolites
The major metabolites include 5:
- Reduced haloperidol (RH) - formed via carbonyl reductase
- Pyridinium metabolite (HP+) - potentially neurotoxic
- 4-(4-chlorophenyl)-4-hydroxypiperidine (CPHP) - N-dealkylation product
- p-Fluorobenzoyl-propionic acid
- Glucuronide conjugates
Clinical Implications
Pharmacogenetic Considerations
Genetic polymorphisms in CYP2D6 significantly affect haloperidol metabolism 6. Approximately 5-8% of Caucasians are poor metabolizers (PMs), while 1-7% are ultrarapid metabolizers (UMs) 6:
- Poor metabolizers: Higher risk for adverse effects due to elevated plasma concentrations
- Ultrarapid metabolizers: Risk for therapeutic failure due to subtherapeutic levels
Consider CYP2D6 genotyping or phenotyping when dose adequacy is uncertain 7, particularly if patients experience unexpected side effects at standard doses or fail to respond to adequate dosing.
Drug Interactions
Haloperidol is both a substrate and modulator of CYP enzymes 1:
CYP3A4 inducers significantly reduce haloperidol levels:
- Rifampin decreases plasma levels by ~70% 8
- Carbamazepine, phenytoin, phenobarbital require dose adjustments 1
CYP3A4 inhibitors increase haloperidol exposure:
- Fluoxetine, fluvoxamine, nefazodone increase concentrations 1
Haloperidol acts as both an inhibitor and stimulator of CYP2D6 1, creating potential for bidirectional interactions.
Age-Related Changes
In elderly patients, hepatic metabolism decreases by 20-50% for CYP450-mediated phase I reactions 9. Combined with:
- Reduced liver mass (20-30%)
- Decreased hepatic blood flow
- Lower plasma albumin (increasing free drug fraction)
This necessitates dose reduction in older patients 10. Guidelines recommend starting at 0.25-0.5 mg in frail elderly patients 10.
Hepatic Impairment
Dose reduction is mandatory in hepatic impairment 10, 8 given haloperidol's high first-pass metabolism (systemic availability 10-70%) 6 and predominant hepatic clearance.
Important Caveats
- Smoking induces CYP1A2 but has minimal direct effect on haloperidol metabolism 7
- Renal impairment has minimal impact on haloperidol clearance since renal excretion is low 6
- The clinical significance of pyridinium metabolites (HP+) remains debated, with concerns about potential neurotoxicity similar to MPTP 5
- Therapeutic drug monitoring may be warranted when drug interactions are suspected or in patients with unexpected responses 6